Latest News

Endeavour Medtech Growth II LP closes at $375m

©Endevour Medtech


by tg

Endeavour Vision has announced the closing of its Heathtech fund  Endeavour Medtech Growth II (EMG II) LP at US$375 million in capital commitments.


The fund will pursue the strategy to support innovative growth-stage medtech and digital health companies.Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices and high-net-worth individuals.

The fund’s closing comes as the world begins to look towards post-pandemic life after more than 12 months in the grip of COVID-19, a crisis that has accelerated the adoption of new healthcare technologies including novel ways of delivering remote patient care, wearables etc. Underlying trends, such as ageing populations, chronic diseases and strained healthcare budgets will continue to fuel demand for cost-efficient solutions. Therefore, healthcare innovation is set to remain a long-term priority that is expected to generate attractive growth and a diverse set of opportunities for investors.

The fund has already supported seven companies with investments of more than US$100 million: IntelyCare, CeQur, Rapid Micro Biosystems, SOPHiA GENETICS, Nalu Medical, Lumeon and Relievant Medsystems.

miRNAs unmask vulnerability in breast cancer stem cells

The study results, published in the Journal of Cell Biology, reveal that targeting these microRNAs sensitivies cancer stem cells to certain...

Next-gen COVID-19 vaccine good in preclinical tests

In contrast to injectable vaccines, the nasal jab seems capablet to induce mucosal immunity which is crucial to eliminate the virus instead only...

J&J starts European COVID-19 vaccine roll-out

According to the EMA, the very rare cases of cerebral venous thrombosis, which were observerd after vaccination with J&J’s COVID-19 jab, didn't...

COVID-19: Study finds neutralising antibodies to disappear rapidly

According to the “Rhineland population-based Study”, published by researchers under  Prof. Monique Breteler at the DZNE in Bonn, Germany blood...

B.1.1.7 variant associated with higher mortality

Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

Record year for Swiss biotech industry

Driven by the corona crisis, the Swiss biotech ecosystem is thriving as never before. This is evidenced by the Swiss Biotech Report from EY, the...

Abingworth raises $582m for late-stage fund ACCD 2

Abingworth Clinical Co-Development Fund 2 (ACCD 2) was significantly oversubscribed, exceeding its target of $350m. The ACCD 2 fund provides finance...